S-TARget therapeutics is a biotech start-up company founded in September 2010, that develops novel therapeutic vaccines to cure and prevent allergic diseases. S-TARget‘s vaccines are based on a unique, proprietary technology platform that addresses the cause of the disease not only the symptoms. They are directed against major, widespread allergic diseases that currently cannot be cured – including severe forms of allergy. Lead candidate SG100 targets allergic asthma induced by house dust mite (HDM), the major cause of allergy in the Western world.
